Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.67 |
| ▸ | KIT | P10721 | 1/20 | 0.67 |
| ▸ | FLT1 | P17948 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.42 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.42 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.40 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.40 |
| ▸ | FASN | P49327 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2860341 | 0.91 | KDR (0.67) | KDRPDGFRBKITFLT1KCNH2 | |
| SCHEMBL2865633 | 0.88 | KDR (0.65) | KDRPDGFRBKITFLT1KCNH2 | |
| SCHEMBL2855759 | 0.87 | KDR (0.76) | KDRPDGFRBKITFLT1KCNH2 | |
| SCHEMBL2881203 | 0.84 | KDR (0.69) | KDRPDGFRBKITFLT1KCNH2 | |
| SCHEMBL2864115 | 0.84 | KDR (0.71) | KDRPDGFRBKITFLT1KCNH2 | |
| SCHEMBL2859425 | 0.84 | KDR (0.71) | KDRPDGFRBKITFLT1KCNH2 | |
| SCHEMBL2864135 | 0.83 | KDR (0.68) | KDRPDGFRBKITFLT1KCNH2 | |
| SCHEMBL3913172 | 0.83 | KDR (0.68) | KDRPDGFRBKITFLT1KCNH2 | |
| SCHEMBL2862369 | 0.83 | KDR (0.68) | KDRPDGFRBKITFLT1KCNH2 | |
| SCHEMBL2862543 | 0.83 | KDR (0.77) | KDRPDGFRBKITFLT1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513818-B1 | HETEROCYCLIC INHIBITORS OF VEGFR-2 KINASES | BRISTOL MYERS SQUIBB CO (US) | 2010-01-20 | — | — | EP | claimed |
| EP-1513818-A4 | HETEROCYCLIC INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-10-04 | — | — | EP | claimed |
| US-20060135576-A1 | Heterocyclic inhibitors of kinases | BORZILLERI ROBERT M | 2006-06-22 | — | — | US | claimed |
| EP-1513818-A2 | HETEROCYCLIC INHIBITORS OF KINASES | Bristol-Myers Squibb Company (US) | 2005-03-16 | — | — | EP | claimed |
| US-20040077696-A1 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | claimed |
| WO-2004001059-A2 | HETEROCYCLIC INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-31 | — | — | WO | claimed |
| EP-1513818-B1 | HETEROCYCLIC INHIBITORS OF VEGFR-2 KINASES | BRISTOL MYERS SQUIBB CO (US) | 2010-01-20 | — | — | EP | disclosed |
| US-7547711-B2 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| EP-1513818-A4 | HETEROCYCLIC INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-10-04 | — | — | EP | disclosed |
| US-7084160-B2 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060135576-A1 | Heterocyclic inhibitors of kinases | BORZILLERI ROBERT M | 2006-06-22 | — | — | US | disclosed |
| EP-1513818-A2 | HETEROCYCLIC INHIBITORS OF KINASES | Bristol-Myers Squibb Company (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040077696-A1 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| WO-2004001059-A2 | HETEROCYCLIC INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135576-A1 | Heterocyclic inhibitors of kinases | FGFR1, FLT1, FGFR2 | KDR 7/4885PDGFRB 27/4885KIT 167/4885 |
| US-20040077696-A1 | Heterocyclic inhibitors of kinases | FGFR1, FLT1, FGFR2 | KDR 6/4885PDGFRB 27/4885KIT 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.